- Conditions
- Wiskott-Aldrich Syndrome
- Interventions
- Patient Interview guide, Caregiver interview guide, Sociodemographic questionnaire, Pediatric quality of life (PedsQL) questionnaire, Clinical questionnaire
- Other
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 12 Years to 30 Years · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Collegeville, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1681–1704
of 80,955
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- PEG-interferon alfa-2b, temozolomide
- Biological · Drug
- Lead sponsor
- Dartmouth-Hitchcock Medical Center
- Other
- Eligibility
- 18 Years to 120 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2002
- U.S. locations
- 1
- States / cities
- Lebanon, New Hampshire
- Conditions
- Ischemia
- Interventions
- Control Group, Single-Dose Heliox Group, Muscle Biopsy
- Procedure
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Chronic Kidney Diseases, Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Diabetes Mellitus, Diabetic Nephropathies
- Interventions
- Allogeneic adipose-derived mesenchymal stem cells (MSC)-Single Infusion, Allogeneic adipose-derived mesenchymal stem cells (MSC)-Two Infusions
- Drug
- Lead sponsor
- LaTonya J. Hickson
- Other
- Eligibility
- 30 Years to 80 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 2
- States / cities
- Jacksonville, Florida • Rochester, Minnesota
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Acute Myeloid Leukemia With Multilineage Dysplasia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
- Interventions
- Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Liposome-encapsulated Daunorubicin-Cytarabine, Pomalidomide
- Procedure · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 11
- States / cities
- Atlanta, Georgia • Kansas City, Kansas • Westwood, Kansas + 8 more
- Conditions
- Opsoclonus-myoclonus Syndrome, Opsoclonus, Myoclonus, Ataxia
- Interventions
- rituximab
- Drug
- Lead sponsor
- National Pediatric Neuroinflammation Organization, Inc.
- Other
- Eligibility
- 6 Months to 19 Years
- Enrollment
- 25 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Springfield, Illinois
- Conditions
- Bipolar Depression, Treatment Resistant Bipolar Depression
- Interventions
- Ketamine, Functional magnetic resonance imaging (fMRI)
- Drug · Other
- Lead sponsor
- Drew Cumming
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 2
- States / cities
- Cleveland, Ohio • Ohio City, Ohio
- Conditions
- Acute Myocardial Infarction, Acute Coronary Syndrome
- Interventions
- high-sensitivity cardiac troponin testing
- Diagnostic Test
- Lead sponsor
- Fred Apple
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 1,559 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2025
- U.S. locations
- 1
- States / cities
- Minneapolis, Minnesota
- Conditions
- Advanced/Metastatic Malignant Solid Tumors
- Interventions
- HLX43, HLX10
- Drug
- Lead sponsor
- Shanghai Henlius Biotech
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 367 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2027
- U.S. locations
- 6
- States / cities
- Stanford, California • Washington D.C., District of Columbia • Chicago, Illinois + 3 more
- Conditions
- Myelodysplastic Syndrome, Acute Myelogenous Leukemia
- Interventions
- 5-Azacytidine (5-aza), Valproic Acid, All-Trans Retinoic Acid (ATRA)
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 3 Years and older
- Enrollment
- 34 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2007
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Liver Cancer
- Interventions
- Not listed
- Lead sponsor
- Rutgers, The State University of New Jersey
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2013
- U.S. locations
- 1
- States / cities
- New Brunswick, New Jersey
- Conditions
- Spinal Fusion
- Interventions
- Dexmedetomidine
- Drug
- Lead sponsor
- Hospital for Special Surgery, New York
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Irritable Bowel Syndrome With Diarrhea (IBS-D)
- Interventions
- DNK333, Placebo
- Drug
- Lead sponsor
- Novartis
- Industry
- Eligibility
- 18 Years to 65 Years · Female only
- Enrollment
- 180 participants
- Timeline
- 2006 – 2007
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • North Little Rock, Arkansas • Los Angeles, California + 34 more
- Conditions
- Fabry Disease
- Interventions
- agalsidase alfa
- Biological
- Lead sponsor
- Shire
- Industry
- Eligibility
- Not listed
- U.S. locations
- 25
- States / cities
- Tucson, Arizona • La Jolla, California • Los Angeles, California + 21 more
- Conditions
- Atrial Fibrillation
- Interventions
- Verily Watch Cardio, iRhythm Zio monitor, Schiller CARDIOVIT FT-1
- Device
- Lead sponsor
- Verily Life Sciences LLC
- Industry
- Eligibility
- 22 Years and older
- Timeline
- 2023 – 2024
- U.S. locations
- 3
- States / cities
- Lakewood, Colorado • Southfield, Michigan • Winston-Salem, North Carolina
- Conditions
- CCU Inpatients
- Interventions
- Not listed
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 0 Months to 18 Years
- Enrollment
- 30 participants
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Inflammatory Bowel Diseases, Crohn Disease, Ulcerative Colitis, Indeterminate Colitis
- Interventions
- Methylprednisolone
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 4 Years to 25 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Palo Alto, California
- Conditions
- Myelodysplastic Syndromes
- Interventions
- bortezomib
- Drug
- Lead sponsor
- University of Rochester
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 8 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2010
- U.S. locations
- 1
- States / cities
- Rochester, New York
- Conditions
- Breast Cancer
- Interventions
- anti-thymocyte globulin, filgrastim, graft-versus-tumor induction therapy, therapeutic allogeneic lymphocytes, cyclosporine, fludarabine phosphate, melphalan, methotrexate, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years to 60 Years · Female only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2003 – 2008
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Chronic Bronchitis
- Interventions
- Guafenesin tablets
- Drug
- Lead sponsor
- American Health Research
- Other
- Eligibility
- 40 Years to 90 Years
- Enrollment
- 82 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 2
- States / cities
- Charlotte, North Carolina • Rock Hill, South Carolina
- Conditions
- Sickle Cell Disease
- Interventions
- Music Therapy
- Behavioral
- Lead sponsor
- University Hospitals Cleveland Medical Center
- Other
- Eligibility
- 18 Years to 35 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Infertility, Female
- Interventions
- Ibuprofen 800 mg oral, Ketorolac 30mg oral
- Drug
- Lead sponsor
- Madigan Army Medical Center
- Federal
- Eligibility
- 18 Years to 45 Years · Female only
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Tacoma, Washington
- Conditions
- Transthyretin (TTR) Mediated Familial Amyloidotic Cardiomyopathy (FAC), Amyloidosis, Hereditary, Amyloid Neuropathies, Familial, Amyloid Neuropathies, Amyloidosis, Hereditary, Transthyretin-Related, Familial Transthyretin Cardiac Amyloidosis
- Interventions
- Revusiran (ALN-TTRSC), Sterile Normal Saline (0.9% NaCl)
- Drug
- Lead sponsor
- Alnylam Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 206 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 41
- States / cities
- Bakersfield, California • Beverly Hills, California • La Mesa, California + 30 more
- Conditions
- Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma, Stage IV Renal Cell Cancer
- Interventions
- Sorafenib Tosylate, Recombinant Interferon Alfa-2b, Laboratory Biomarker Analysis
- Drug · Biological · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas